Salary
Advice & Tips
Jobs Open Hiring
Calculate Your Salary Ranking
Home > Pulmatrix Salary

Pulmatrix Salary

Pulmatrix average salary is $69,727, median salary is $69,727 with a salary range from $54,454 to $85,000.
Pulmatrix salaries are collected from government agencies and companies. Each salary is associated with a real job position. Pulmatrix salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Low
54,454
Average
69,727
Median
69,727
High
85,000
Total 2 Pulmatrix Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More Info
Formulation Scientist 54,454-54,454 Lexington, MA, 02173 2008 Pulmatrix Formulation Scientist Salaries (1)
Pulmatrix Lexington, MA Salaries
Pharmaceutical & Device Dvlpmt, Associate Director 85,000-85,000 Cambridge, MA, 02138 2007 Pulmatrix Pharmaceutical & Device Dvlpmt, Associate Director Salaries (1)
Pulmatrix Cambridge, MA Salaries
1
Pulmatrix Jobs
Calculate how much you could earn

It's FREE. Based on your input and our analysis.    How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address
Recent Pulmatrix Salaries (May 24, 2012)
Genetics Research Analyst Histogenetics $44,866 Ossining, NY, 10562 09/06/2010
Registered Nurse - Medical Intensive Care UCLA $86,736 Los Angeles, CA, 90001 04/01/2010

Pulmatrix salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Pulmatrix Information
  • Pulmatrix
  • Industry: Biotech/Healthcare
  • City: Lexington, MA
  • Pulmatrix was founded in 2003 and is based on the ground breaking work of Harvard University Professor David Edwards. Mr. Gabrielson and Dr. Edwards co-founded the company with MIT Professors Bob Langer and Alexander Klibanov. Pulmatrix is financed by Polaris Venture Partners and 5AM Ventures. Pulmatrix¡¯s lead therapeutic program should enter a Phase I clinical study this quarter.
  • Pulmatrix Profile
  • Robert Connelly